Stock AKYA AKOYA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Akoya Biosciences, Inc.

Equities

AKYA

US00974H1041

Market Closed - Nasdaq
Other stock markets
 21:00:00 14/05/2024 BST 		5-day change 1st Jan Change
2.9 USD -29.61% Intraday chart for Akoya Biosciences, Inc. -28.92% -40.57%
07:56pm Top Midday Decliners MT
02:33pm Top Premarket Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
MT
Top Premarket Decliners
MT
Exchange-Traded Funds Mixed, Equity Futures Higher Pre-Bell Tuesday Ahead of Powell Speech
MT
Akoya Biosciences Sinks Over 30% in Late-Hours Activity Monday as Q1 Sales Miss Capital IQ Estimate
MT
Transcript : Akoya Biosciences, Inc., Q1 2024 Earnings Call, May 13, 2024
Akoya: Q1 Earnings Snapshot
AQ
Earnings Flash (AKYA) AKOYA BIOSCIENCES Reports Q1 Revenue $18.4M, vs. Street Est of $24.3M
MT
Akoya Biosciences Reports First Quarter 2024 Financial Results
GL
Akoya Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
GL
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
AQ
Akoya Biosciences, Inc. and NeraCare Enters into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
CI
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
GL
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
AQ
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
CI
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
GL
Akoya Biosciences and Shanghai KR Pharmtech Announces Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
CI
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
GL
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
GL
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AKYA Stock
  4. News Akoya Biosciences, Inc.